Stryker is no longer being priced as the medtech compounder that simply outgrows the group. The second-quarter print showed demand and production coming back after a March cyber disruption of the Microsoft environment. Organic sales advanced at a high-single-digit rate even against a double-digit year-ago compare. The market still sold the equity because the second-half bar implied by narrowed full-year guidance is steeper than the quarter just delivered. A Peripheral Vascular plant problem is now stretching past the original third-quarter fix.
The operating story is a volume recovery, not a price recovery. Consolidated net sales reached $6.6 billion. Organic growth printed at 9.0 percent and was almost entirely unit volume, with pricing described as flat. Adjusted operating margin rose 170 bps. The adjusted rate reached 27.4 percent, helped by mix, spend discipline, and a net tariff benefit that is not a permanent feature of the model. Vascular sales in the United States declined because a single Inari plant could not keep the field stocked.
Kevin Lobo framed the quarter as regained momentum after the cyber event. Organic sales guidance was narrowed to a band from 8.3 percent to 9.3 percent. Preston Wells later told the Wells Fargo Healthcare Conference that the Peripheral Vascular constraint now runs into the fourth quarter and still blocks a full return to winning new accounts. The investment debate is whether the reset near $275 is paying for a timing problem or for lasting share loss in emergency vascular work.